Baseline and treatment characteristics of individuals, by LDL-cholesterol treatment goal attainment at 12 months (n=3064)
| Patient or treatment characteristics | Unit | Total N (%) | LDL-C goal attained N (%) | LDL-C goal not attained N (%) | P value |
| 3064 (100) | 895 (29.21) | 2169 (70.79) | |||
| Women | N (%) | 1873 (61.13) | 590 (65.92) | 1283 (59.15) | <0.001 |
| Ethnicity | N (%) | ||||
| White | 1610 (91.74) | 452 (92.24) | 1158 (91.54) | ||
| Asian/British Asian | 74 (4.22) | 10 (4.08) | 54 (4.27) | 0.366 | |
| Black/Black British | 27 (1.54) | 7 (1.43) | 20 (1.58) | ||
| Mixed | 10 (0.57) | 0 | 10 (0.79) | ||
| Others | 34 (1.94) | 11 (2.24) | 23 (1.83) | ||
| Age (years) at FH diagnosis | Mean (SD) | 50.79 (13.13) | 53.44 (12.60) | 49.71 (13.20) | <0.001 |
| Age (years) at first statin | Mean (SD) | 50.33 (12.83) | 53.18 (12.48) | 49.16 (12.80) | <0.001 |
| Pretreatment total cholesterol (mmol/L) | Mean (SD) | 7.76 (1.42) | 8.20 (1.38) | 7.57 (1.39) | <0.001 |
| Pretreatment LDL-C (mmol/L) | Mean (SD) | 5.42 (1.41) | 5.83 (1.36) | 5.25 (1.40) | <0.001 |
| Post-treatment LDL-C (12 months) (mmol/L) | Mean (SD) | 3.45 (1.37) | 2.43 (0.63) | 3.88 (1.37) | <0.001 |
| Pretreatment HDL-C (mmol/L) | Mean (SD) | 1.50 (0.49) | 1.59 (0.57) | 1.46 (0.45) | <0.001 |
| Pretreatment triglycerides (mmol/L) | Mean (SD) | 1.70 (1.20–2.47) | 1.70 (1.20–2.47) | 1.70 (1.20–2.46) | 0.5087 |
| Statin potency at baseline | N (%) | ||||
| Low | 264 (8.62) | 36 (4.02) | 225 (10.51) | ||
| Medium | 2145 (70.01) | 642 (71.73) | 1503 (69.29) | <0.001 | |
| High | 655 (21.38) | 217 (24.25) | 438 (20.19) | ||
| Statin potency at 6 months | N (%) | ||||
| Low | 188 (6.14) | 26 (2.91) | 162 (7.47) | ||
| Medium | 1571 (51.27) | 485 (54.19) | 1086 (50.07) | <0.0001 | |
| High | 772 (25.20) | 298 (33.30) | 474 (21.85) | ||
| Missing record | 533 (17.40) | 86 (9.61) | 447 (20.61) | ||
| Statin potency at 12 months | N (%) | ||||
| Low | 142 (4.63) | 17 (1.90) | 125 (5.76) | <0.0001 | |
| Medium | 1225 (39.98) | 426 (47.60) | 799 (36.84) | ||
| High | 775 (25.29) | 301 (33.63) | 474 (21.85) | ||
| Missing record | 922 (30.09) | 151 (16.87) | 771 (35.55) | ||
| Cigarette smoking status at baseline | N (%) | n=2126 | n=615 | n=1511 | |
| Current | 628 (29.54) | 160 (26.02) | 468 (30.97) | <0.001 | |
| Ex | 461 (21.68) | 135 (21.95) | 326 (21.58) | ||
| Never | 1037 (48.78) | 320 (52.03) | 717 (47.45) | ||
| Alcohol misuse (yes) | N (%) | 35 (1.14) | 14 (1.56) | 21 (0.97) | 0.158 |
| Atrial fibrillation | N (%) | 18 (0.59) | 8 (0.89) | 10 (0.46) | 0.154 |
| Chronic kidney disease | N (%) | 40 (1.31) | 19 (2.12) | 21 (0.97) | 0.01 |
| Hypertension | N (%) | 406 (13.25) | 120 (13.41) | 286 (13.19) | 0.869 |
| Type 2 diabetes | N (%) | 45 (1.47) | 15 (1.68) | 30 (1.38) | 0.54 |
| Obesity/overweight | N (%) | 320 (10.44) | 97 (10.84) | 223 (10.28) | 0.647 |
| Physical activity level | N (%) | n=331 | n=94 | n=237 | |
| Extremely inactive | 23 (6.95) | 7 (7.45) | 16 (6.75) | 0.54 | |
| Sedentary | 29 (8.76) | 7 (7.45) | 22 (9.28) | ||
| Moderately active | 271 (81.87) | 76 (80.85) | 195 (82.28) | ||
| Extremely active | 8 (2.42) | 4 (4.26) | 4 (1.69) | ||
| Use of other medications | N (%) | ||||
| Antipsychotics | 418 (13.64) | 148 (16.54) | 270 (12.45) | 0.003 | |
| Corticosteroids | 292 (9.53) | 108 (12.07) | 184 (8.48) | 0.002 |
FH, familial hypercholesterolaemia; HDL, high-density lipoprotein; LDL, low-density lipoprotein.